AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6110955
Drug: Low-dose cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose cisplatin, chlorambucil, and doxorubicin
Trial: 27737714
Drug: Mindfulness-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based Cognitive Therapy (MBCT)
Trial: 20961444
Drug: Maintenance anti-depressant
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance anti-depressant treatment (m-ADM)
Trial: 7141754
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg rectal pretreatment)
Trial: 7141754
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (300 mg)
Trial: 31924519
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation (immediate physical therapy for passive and active ROM)
Trial: 30036672
Drug: Clofazimine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine (100 mg per day)
Trial: 23377024
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg (no caffeine) with 4.3% alcohol
Trial: 23377024
Drug: Caffeine 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 62.5 mg with 4.3% alcohol
Trial: 23377024
Drug: Caffeine 125
RxNorm normalized name: caffeine 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 125 mg with 4.3% alcohol
Trial: 23377024
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg (no caffeine) with no alcohol
Trial: 23377024
Drug: Caffeine 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 62.5 mg with no alcohol
Trial: 23377024
Drug: Caffeine 125
RxNorm normalized name: caffeine 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 125 mg with no alcohol
Trial: 19767090
Drug: Oestrogen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen plus progestin (0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate)
Trial: 17573745
Drug: Parenteral Gln
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Gln (1 g/kg/day) with enteral nutrition (Ensure)
Trial: 14739803
Drug: Ketamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine at 200 ng/ml (analgesic, subanesthetic)
Trial: 14739803
Drug: Ketamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine at 50 ng/ml (subanalgesic)
Trial: 20102918
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg twice daily
Trial: 8507122
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg twice daily
Trial: 8507122
Drug: Cholestyramine 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 24 g daily
Trial: 8507122
Drug: Cholestyramine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 12 g twice daily with Pravastatin 40 mg
Trial: 8507122
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 or 80 mg daily
Trial: 8507122
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Cholestyramine + Pravastatin)
Trial: 29996833
Drug: Post-discharge malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge malaria chemoprevention (PMC) with antimalarial drugs for 3 months post-discharge.
Trial: 29996833
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of health cards for treatment reminders.
Trial: 29996833
Drug: Dihydroartemisinin-piperaquine as
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine as the antimalarial drug.
Trial: 18480672
Drug: Upstream tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upstream tirofiban therapy
Trial: 18480672
Drug: Downstream tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Downstream tirofiban therapy
Trial: 18480672
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (primary PCI treatment alone)
Trial: 14520850
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg twice a day
Trial: 14520850
Drug: Metoprolol 25-50
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 25-50 mg twice a day
Trial: 14520850
Drug: Bisoprolol 5-10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5-10 mg once a day
Trial: 11755543
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (n = 105)
Trial: 9371346
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (saquinavir, zidovudine, zalcitabine)
Trial: 9371346
Drug: Saquinavir and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir and zidovudine combination
Trial: 1531855
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) combined with chemotherapy
Trial: 28202885
Drug: Conventional diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuretic therapy
Trial: 31663690
Drug: Dexmedetomidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (2 μg kg‐1 perioperatively)
Trial: 25201095
Drug: Animal-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted therapy (therapy dog visitation for 15 minutes before physical therapy)
Trial: 25201095
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative physical therapy regimens
Trial: 15531007
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg/d
Trial: 15531007
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg/d
Trial: 9645896
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (1.5 mg/kg body weight, maximum 150 mg)
Trial: 9645896
Drug: Intravenous sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sotalol (1.5 mg/kg body weight, maximum 150 mg)
Trial: 7840710
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy including indomethacin, essential and dimephosphone
Trial: 7840710
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of pathogenetic and antibacterial drugs (monomycin, kanamycin, polymyxin, gentamicin)
Trial: 2906248
Drug: N‐696 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐696 (30 mg/d for 7 days)
Trial: 2906248
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 mg/d for 7 days)
Trial: 24021498
Drug: Methylphenidate 20
RxNorm normalized name: METHYLPHENIDATE 20MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 20 mg daily
Trial: 30232597
Drug: Rifaximin 1200
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1200 mg for 14 days
Trial: 29201297
Drug: Polmacoxib 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polmacoxib 2 mg
Trial: 23819122
Drug: Mydriasert insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mydriasert insert (0.28 mg of tropicamide and 5.4 mg of phenylephrine hydrochloride)
Trial: 19922034
Drug: Non-exercising delayed-treatment
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exercising delayed-treatment control group (DTC)
Trial: 16773694
Drug: N-acetylcysteine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (two 600 mg doses orally 24 and 12 hours before ERCP and 600 mg IV, twice a day for two days after ERCP)
Trial: 16773694
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (IV, twice a day for two days after ERCP)
Trial: 15519704
Drug: Viatim vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viatim vaccine
Trial: 15519704
Drug: Hepatyrix vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatyrix vaccine
Trial: 11760147
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (8 mg PO every 8 hours)
Trial: 11760147
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron (1 mg PO every 12 hours)
Trial: 11760147
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron (32 mg IV every 24 hours)
Trial: 9919425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued regular treatment)
Trial: 8115153
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin treatment
Trial: 24104372
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine treatment (1g/m2 d 1, 8, 15, q 4 weeks for 6 months)
Trial: 20628405
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg silybin (Legalon Forte) with a vegetarian meal containing 13.9 mg iron
Trial: 20628405
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml water
Trial: 20628405
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml tea
Trial: 18172039
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pravastatin 10 to 20 mg/d
Trial: 18172039
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pravastatin 10 to 20 mg/d (women ≥ 60 years)
Trial: 16948756
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (amiodarone 5 mg/kg and MgSO(4) 1.5 g)
Trial: 16948756
Drug: Amiodarone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone group (amiodarone 5 mg/kg)
Trial: 14558738
Drug: Cefaclor 375
RxNorm normalized name: cefaclor 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 375 mg twice daily
Trial: 2140547
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice daily
Trial: 7913970
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment for 1 to 4 months
Trial: 7913970
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment for 4 months
Trial: 7913970
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment for 1-22 months
Trial: 7913970
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment for 3-13 months
Trial: 3061974
Drug: Glucagon (0.25-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (0.25-2 mg, administered intravenously or intramuscularly)
Trial: 25063274
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon
Trial: 29949232
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin (2 capsules, 5 mg each) once a day for 12 weeks
Trial: 24005956
Drug: Simeprevir 50
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 50 mg QD with PegIFNα‐2a/RBV for 24 weeks
Trial: 24005956
Drug: Simeprevir 100
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 100 mg QD with PegIFNα‐2a/RBV for 24 weeks
Trial: 21761708
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of correction of deviated nasal septum and plasma radiofrequency ablation
Trial: 21761708
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of deviated nasal septum and partial inferior turbinectomy
Trial: 19476470
Drug: Repaglinide/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide/metformin FDC tablet BID
Trial: 19476470
Drug: Rosiglitazone/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone/metformin FDC tablet BID
Trial: 15179410
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg subcutaneously, administered twice daily on days 1 to 7)
Trial: 7657854
Drug: 80-mg orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80-mg orlistat three times a day for 4 1/3 days
Trial: 8458364
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 mg)
Trial: 797075
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Trial: 797075
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Trial: 28745783
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous catheter fixation
Trial: 28745783
Drug: Modified intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified intravenous catheter fixation
Trial: 25560571
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus metformin
Trial: 23958390
Drug: Up-titration of
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-titration of metformin monotherapy
Trial: 19172219
Drug: Menatetrenone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (45 mg daily for 6 months)
Trial: 19172219
Drug: Calcium aspartate
RxNorm normalized name: calcium aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium aspartate (133.8 mg of elemental calcium daily)
Trial: 17234537
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of lycopene (Group A, n = 21)
Trial: 17234537
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of lycopene along with biweekly intralesional steroid injections (Group B, n = 19)
Trial: 8959872
Drug: CsA monotherapy
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA monotherapy
Trial: 11562416
Drug: CsA +
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA + steroids (dual therapy)
Trial: 11562416
Drug: CsA +
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA + steroids + azathioprine (triple therapy)
Trial: 11562416
Drug: CsA monotherapy
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA monotherapy with steroids added
Trial: 9565278
Drug: Dentine bonding
RxNorm normalized name: dendropanax dentiger root with stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentine bonding agent (DBA)
Trial: 1792323
Drug: Boost dose
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost dose in breast conserving therapy
Trial: 1792323
Drug: Treatment planning
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment planning techniques
Trial: 1792323
Drug: Dose specification
RxNorm normalized name: SPECIFIC GRAVITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose specification
Trial: 1792323
Drug: Dose recalculation
RxNorm normalized name: CAP,UNIVERSAL,TRACH DECANNULATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose recalculation
Trial: 27988390
Drug: Mechanical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical therapy with adjunctive metronidazole
Trial: 27988390
Drug: Mechanical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical therapy without adjunctive metronidazole
Trial: 26013203
Drug: Aripiprazole augmentation
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole augmentation (AA)
Trial: 26013203
Drug: Antidepressant switching
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant switching (SW)
Trial: 26013203
Drug: Aripiprazole augmentation
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole augmentation (AA) and Antidepressant switching (SW)
Trial: 24725616
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro low mixture (LM25) twice daily
Trial: 24725616
Drug: Basal-prandial regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-prandial regimen of insulin glargine once daily and insulin lispro once daily (IGL)
Trial: 15761427
Drug: 1064-nm neodymium:yttrium-aluminum-garnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at minimum purpura dose (MPD)
Trial: 10467790
Drug: Reformulated 2-rod
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated 2-rod Norplant implant
Trial: 8922875
Drug: Original 2-rod
RxNorm normalized name: hexylresorcinol 2.4 MG [Sucrets Original]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original 2-rod Norplant implant
Trial: 1417482
Drug: Supranormal values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supranormal values of cardiac index (> or = 4.52 L/min per square meter), oxygen delivery (> or = 670 mL/min per square meter), and oxygen consumption (> or = 166 mL/min per square meter)
Trial: 4084899
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose 3.78 mg)
Trial: 4084899
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean daily dose 208 mg)
Trial: 17484740
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention guided by the Levine Conservation Model; details on dosage and duration not specified.
Trial: 15192321
Drug: Asymmetric dimethylarginine
RxNorm normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric dimethylarginine (ADMA) infusion
Trial: 11336588
Drug: Saquinavir (Fortovase)
RxNorm normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saquinavir (Fortovase) co-administered with nucleoside reverse transcriptase inhibitors (nRTIs)
Trial: 11336588
Drug: Saquinavir (Fortovase)
RxNorm normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saquinavir (Fortovase) co-administered with ritonavir
Trial: 11336588
Drug: Saquinavir (Fortovase)
RxNorm normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saquinavir (Fortovase) co-administered with nelfinavir